{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:46:23Z","timestamp":1791225983181,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002924","name":"FEDER funds through the Programa Operacional Factores de Competitividade\u2014COMPETE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\u2014Portuguese Foundation for Science and Technology","doi-asserted-by":"publisher","award":["PTDC\/SAU-FAR\/115044\/2009"],"award-info":[{"award-number":["PTDC\/SAU-FAR\/115044\/2009"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT\u2014Portuguese Foundation for Science and Technology","doi-asserted-by":"publisher","award":["PEst-C\/SAU\/LA0001\/2013-2014"],"award-info":[{"award-number":["PEst-C\/SAU\/LA0001\/2013-2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT doctoral fellowship","doi-asserted-by":"publisher","award":["SFRH\/BD\/65141\/2009"],"award-info":[{"award-number":["SFRH\/BD\/65141\/2009"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.vaccine.2015.06.037","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T19:09:16Z","timestamp":1434395356000},"page":"3609-3613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination"],"prefix":"10.1016","volume":"33","author":[{"given":"Dulce","family":"Bento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman F.","family":"Staats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-5121","authenticated-orcid":false,"given":"Olga","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.06.037_bib0095","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1016\/j.vaccine.2010.10.006","article-title":"A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection","volume":"28","author":"Wilson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0100","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.vaccine.2009.01.118","article-title":"The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice","volume":"27","author":"Kovacs-Nolan","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/JVI.76.2.517-524.2002","article-title":"Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization","volume":"76","author":"Bradney","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0110","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants","volume":"10","author":"Schijns","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0115","doi-asserted-by":"crossref","first-page":"e16532","DOI":"10.1371\/journal.pone.0016532","article-title":"Mucosal targeting of a BoNT\/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT\/A neutralizing antibodies in rabbits","volume":"6","author":"Staats","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0120","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1016\/j.vaccine.2009.03.069","article-title":"The mast cell activator compound 48\/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen","volume":"27","author":"McGowen","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0125","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nm1757","article-title":"Mast cell activators: a new class of highly effective vaccine adjuvants","volume":"14","author":"McLachlan","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0130","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.vaccine.2013.01.012","article-title":"A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen","volume":"31","author":"Gwinn","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0135","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.vaccine.2015.01.013","article-title":"Compound 48\/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice","volume":"33","author":"Zeng","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.037_bib0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4161\/21645515.2014.995056","article-title":"Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48\/80 adjuvant","volume":"11","author":"Zheng","year":"2015","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.colsurfb.2007.04.009","article-title":"Chitosan nanoparticle as protein delivery carrier \u2013 systematic examination of fabrication conditions for efficient loading and release","volume":"59","author":"Gan","year":"2007","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0150","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1208\/s12249-013-9950-4","article-title":"Validation of a new 96-well plate spectrophotometric method for the quantification of compound 48\/80 associated with particles","volume":"14","author":"Bento","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0155","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.4049\/jimmunol.1100254","article-title":"Maximal adjuvant activity of nasally delivered IL-1alpha requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production","volume":"188","author":"Thompson","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0160","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/IAI.00529-07","article-title":"In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity","volume":"75","author":"Staats","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpb.2015.03.024","article-title":"Development of a novel adjuvanted nasal vaccine: C48\/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity","volume":"93","author":"Bento","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0170","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11095-005-9078-7","article-title":"Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles","volume":"23","author":"Sloat","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0175","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/IAI.00070-07","article-title":"Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge","volume":"75","author":"Bielinska","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.06.037_bib0180","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.4049\/jimmunol.170.11.5636","article-title":"Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen","volume":"170","author":"Boyaka","year":"2003","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15008269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15008269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:21:26Z","timestamp":1759400486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15008269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":18,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0264410X15008269"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}